Dataset: Transcription profiling of human inflammatory breast carcinoma tumors (luminal, basal and apocrine)
EORTC 10994 is a phase III clinical trial comparing FEC with ET in patients with large operable, locally advanced or inflammatory breast...
EORTC 10994 is a phase III clinical trial comparing FEC with ET in patients with large operable, locally advanced or inflammatory breast cancer (www.eortc.be). Frozen biopsies were taken at randomisation. RNA was extracted from 100um thickness of 14G core needle biopsies. Adjacent sections were tested by H&E to confirm >20% tumour cell content. 100 ng total RNA per chip were amplified using the Affymetrix small sample protocol (IVT then Enzo). 49 tumours were tested on Affymetrix U133A chips. The CEL files were quantile normalised together using rma. Clinical response data are not available yet. See doi:10.1038/sj.onc.1208561 Farmer et al "Identification of molecular apocrine breast tumours by microarray analysis
- Species:
- human
- Samples:
- 49
- Source:
- E-GEOD-1561
- PubMed:
- 15897907
- Updated:
- Dec.12, 2014
- Registered:
- Jun.20, 2014
Sample | TumorGrading | DiseaseStaging |
---|---|---|
GSE1561GSM26886 | apocrine tumor | T2N1G2 |
GSE1561GSM26882 | basal tumor | T2N1G3 |
GSE1561GSM26872 | luminal tumor | T2N0G2 |
GSE1561GSM26897 | luminal tumor | TiN0G2 |
GSE1561GSM26875 | luminal tumor | T3N1G2 |
GSE1561GSM26868 | luminal tumor | T3N0Gu |
GSE1561GSM26894 | luminal tumor | T2N0G3 |
GSE1561GSM26869 | luminal tumor | T2N1G1 |
GSE1561GSM26903 | apocrine tumor | T4N0Gu |
GSE1561GSM26914 | luminal tumor | T3N1G3 |
GSE1561GSM26898 | basal tumor | T3N1G3 |
GSE1561GSM26914 | luminal tumor | T3N1G3 |
GSE1561GSM26890 | luminal tumor | T3N0G3 |
GSE1561GSM26887 | apocrine tumor | T2N0G2 |
GSE1561GSM26875 | luminal tumor | T3N1G2 |
GSE1561GSM26875 | luminal tumor | T3N1G2 |
GSE1561GSM26881 | luminal tumor | T2N1G3 |
GSE1561GSM26867 | luminal tumor | T4N1G2 |
GSE1561GSM26882 | basal tumor | T2N1G3 |
GSE1561GSM26910 | apocrine tumor | T4N1G3 |
GSE1561GSM26882 | basal tumor | T2N1G3 |
GSE1561GSM26869 | luminal tumor | T2N1G1 |
GSE1561GSM26898 | basal tumor | T3N1G3 |
GSE1561GSM26900 | basal tumor | T2N0G2 |
GSE1561GSM26867 | luminal tumor | T4N1G2 |
GSE1561GSM26872 | luminal tumor | T2N0G2 |
GSE1561GSM26904 | luminal tumor | T4N0G2 |
GSE1561GSM26897 | luminal tumor | TiN0G2 |
GSE1561GSM26908 | basal tumor | T3N0G3 |
GSE1561GSM26879 | luminal tumor | TiN1G3 |
GSE1561GSM26886 | apocrine tumor | T2N1G2 |
GSE1561GSM26895 | basal tumor | T2N0G3 |
GSE1561GSM26881 | luminal tumor | T2N1G3 |
GSE1561GSM26907 | luminal tumor | T2N1G2 |
GSE1561GSM26895 | basal tumor | T2N0G3 |
GSE1561GSM26907 | luminal tumor | T2N1G2 |
GSE1561GSM26895 | basal tumor | T2N0G3 |
GSE1561GSM26884 | basal tumor | T3N1G2 |
GSE1561GSM26895 | basal tumor | T2N0G3 |
GSE1561GSM26889 | basal tumor | T3N2G2 |
GSE1561GSM26869 | luminal tumor | T2N1G1 |
GSE1561GSM26906 | basal tumor | T2N2G3 |
GSE1561GSM26884 | basal tumor | T3N1G2 |
GSE1561GSM26869 | luminal tumor | T2N1G1 |
GSE1561GSM26904 | luminal tumor | T4N0G2 |
GSE1561GSM26867 | luminal tumor | T4N1G2 |
GSE1561GSM26875 | luminal tumor | T3N1G2 |
GSE1561GSM26888 | basal tumor | TiN0G3 |
GSE1561GSM26903 | apocrine tumor | T4N0Gu |